脊柱转移性骨病变手术后症状性静脉血栓栓塞风险高:一项回顾性研究
该回顾性研究纳入2002至2014年两家医院637例因脊柱转移瘤接受手术的成人患者,评估术后90天内症状性静脉血栓栓塞(VTE)的发生比例、相关因素、与1年生存的关联及化学预防与伤口并发症的关系。结果显示11%发生症状性VTE,手术时间延长与VTE风险独立相关,发生VTE者1年生存率较低,化学预防与伤口并发症无关联。
要点
- 637例脊柱转移瘤手术患者中,11%在术后90天内发生症状性VTE,6%发生肺栓塞(其中1.3%致命),6%发生深静脉血栓。
- 手术时间每增加1小时,症状性VTE风险独立增加(OR 1.15;95%CI 1.04-1.28;p=0.009)。
- 发生症状性VTE者1年生存率38%(95%CI 27-49)低于无VTE者47%(95%CI 42-51),p=0.044。
核心结论
- 该患者群体中症状性肺栓塞和致命性肺栓塞风险较高,发生症状性VTE者1年生存可能性低于未发生者,但这可能反映总体虚弱状况,因为许多患者并非死于VTE相关并发症。
- 需要进一步研究,如采用一致的术后VTE筛查比较不同化学预防方案的随机对照试验,以确定更好的VTE预防策略。
研究设计与样本
- 回顾性研究,纳入2002至2014年两家医院637例因颈椎、胸椎或腰椎转移(包括淋巴瘤和多发性骨髓瘤)接受手术的成人患者。
- 术后90天和1年分别有21例(3%)和41例(6%)失访。
- 证据等级为III级,治疗性研究。
主要发现
- 637例中72例(11%)发生症状性VTE;38例(6%)发生肺栓塞,其中8例(1.3%)致命;40例(6%)发生深静脉血栓。
- 控制年龄、改良Charlson合并症指数、内脏转移和化学预防等混杂变量后,手术时间延长与症状性VTE风险增加独立相关(每增加1小时,OR 1.15;95%CI 1.04-1.28;p=0.009)。
- 控制年龄、改良Charlson合并症指数、内脏转移和原发肿瘤类型等混杂变量后,症状性VTE患者1年生存率较低(VTE组38%;95%CI 27-49 vs 非VTE组47%;95%CI 42-51;p=0.044)。
- 控制相关混杂变量后,伤口并发症与化学预防使用无关联(OR 1.34;95%CI 0.62-2.90;p=0.459)。
- 总体伤口并发症发生比例为10%(66/637),包括1.1%(7/637)脊髓硬膜外血肿。
关键数值与推荐
- 化学预防一般使用依诺肝素40 mg或皮下肝素5000 IU每12小时一次;术前已用化学预防者术后继续原用药。
- 所有化学预防均在术后48小时开始并逐日持续,若发生出血并发症则停用。
- 低分子量肝素(包括依诺肝素和达肝素,一般剂量分别为40 mg和5000 IU每日)是最常用化学预防,用于308例(48%);皮下肝素用于127例(20%);阿司匹林用于92例(14%);华法林用于21例(3.3%);89例(14%)未接受任何化学预防。
- 主要结局VTE定义为术后90天内经病历回顾确定的任何症状性肺栓塞或症状性深静脉血栓栓塞;次要结局为术后90天内任何可能归因于化学预防的记录的伤口并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer and spinal surgery are both considered risk factors for venous thromboembolism (VTE). However, the risk of symptomatic VTE for patients undergoing surgery for spine metastases remains undefined. QUESTIONS/PURPOSES: The purposes of this study were to: (1) identify the proportion of patients who develop symptomatic VTE within 90-days of surgical treatment for spine metastases; (2) identify the factors associated with the development of symptomatic VTE among patients receiving surgery for spine metastases; (3) assess the association between the development of postoperative symptomatic VTE and 1-year survival among patients who underwent surgery for spine metastases; and (4) assess if chemoprophylaxis increases the risk of wound complications among patients who underwent surgery for spine metastases. METHODS: Between 2002 and 2014, 637 patients at two hospitals underwent spine surgery for metastases. We considered eligible for analysis adult patients whose procedures were to treat cervical, thoracic, or lumbar metastases (including lymphoma and multiple myeloma). At followup after 90 days and 1 year, respectively, 21 of 637 patients (3%) and 41 of 637 patients (6%) were lost to followup. In general, we used 40 mg of enoxaparin or 5000 IUs subcutaneous heparin every 12 hours. Patients on preoperative chemoprophylaxis continued their initial medication postoperatively. All chemoprophylaxis was started 48 hours after surgery and continued day to day but was discontinued if a bleeding complication developed. Low-molecular-weight heparin (including enoxaparin and dalteparin, in general dosages of respectively 40 mg and 5000 IUs daily) was the most commonly used chemoprophylaxis in 308 patients (48%). Subcutaneous heparin was injected into 127 patients (20%); aspirin was used for 92 patients (14%); and warfarin was administered in 21 patients (3.3%). No form of chemoprophylaxis was prescribed for 89 patients (14%). The primary outcome variable, VTE, was defined as any symptomatic pulmonary embolism (PE) or symptomatic deep venous thromboembolism (DVT) within 90 days of surgery as determined by chart review. The secondary outcome was defined as any documented wound complication within 90 days of surgery that might be attributable to chemoprophylaxis. Statistical analysis was performed using multivariable logistic and Cox regression and Kaplan-Meier. RESULTS: Overall, 72 of 637 patients (11%) had symptomatic VTE; 38 (6%) developed a PE-eight (1.3%) of which were fatal-and 40 (6%) a DVT. After controlling for relevant confounding variables such as age, the modified Charlson Comorbidity Index, visceral metastases, and chemoprophylaxis, longer duration of surgery was independently associated with an increased risk of symptomatic VTE (odds ratio 1.15 for each additional hour of surgery; 95% confidence interval [CI], 1.04-1.28; p = 0.009). After controlling for relevant confounding variables such as age, the modified Charlson Comorbidity Index, visceral metastases, and primary tumor type, patients with symptomatic VTE had a worse 1-year survival rate (VTE, 38%; 95% CI, 27-49 versus nonVTE, 47%; 95% CI, 42-51; p = 0.044). After controlling for relevant confounding variables, no association was found between wound complications and the use of chemoprophylaxis (odds ratio, 1.34; 95% CI, 0.62-2.90; p = 0.459). The overall proportion of patients who developed a wound complication was 10% (66 of 637), including 1.1% (seven of 637) spinal epidural hematomas. CONCLUSIONS: The risk of both symptomatic PE and fatal PE is high in this patient population, and those with symptomatic VTE were less likely to survive 1-year than those who did not, though this may reflect overall infirmity as much as anything else, because many of these patients did not die from VTE-related complications. Further study, such as randomized controlled trials with consistent postoperative VTE screening comparing different chemoprophylaxis regimens, are needed to identify better VTE prevention strategies. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Groot OQ, Ogink PT, Paulino Pereira NR, et al. High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study. Clin Orthop Relat Res. 2019. PMID: 31135550. doi:10.1097/CORR.0000000000000733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。